ATE377758T1 - Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen - Google Patents

Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen

Info

Publication number
ATE377758T1
ATE377758T1 AT03818362T AT03818362T ATE377758T1 AT E377758 T1 ATE377758 T1 AT E377758T1 AT 03818362 T AT03818362 T AT 03818362T AT 03818362 T AT03818362 T AT 03818362T AT E377758 T1 ATE377758 T1 AT E377758T1
Authority
AT
Austria
Prior art keywords
bmaa
derivative
neurotoxic
amino acid
environmental sample
Prior art date
Application number
AT03818362T
Other languages
English (en)
Inventor
Paul Cox
Sandra Banack
Susan Murch
Original Assignee
Inst Ethnomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Ethnomedicine filed Critical Inst Ethnomedicine
Application granted granted Critical
Publication of ATE377758T1 publication Critical patent/ATE377758T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03818362T 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen ATE377758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49468603P 2003-08-12 2003-08-12

Publications (1)

Publication Number Publication Date
ATE377758T1 true ATE377758T1 (de) 2007-11-15

Family

ID=34215892

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03818362T ATE377758T1 (de) 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen
AT07018126T ATE520033T1 (de) 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07018126T ATE520033T1 (de) 2003-08-12 2003-12-08 Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen

Country Status (10)

Country Link
US (5) US7256002B2 (de)
EP (2) EP1664793B9 (de)
JP (1) JP4312203B2 (de)
CN (1) CN100595588C (de)
AT (2) ATE377758T1 (de)
AU (1) AU2003296424A1 (de)
CA (1) CA2535663C (de)
DE (1) DE60317379T2 (de)
DK (1) DK1664793T3 (de)
WO (1) WO2005019830A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019830A1 (en) * 2003-08-12 2005-03-03 Institute For Ethnomedicine Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders
US7932287B2 (en) * 2004-08-12 2011-04-26 Chemgenes Corporation Therapeutic compositions and uses
EP3203235A1 (de) 2005-05-23 2017-08-09 Harald F. Hess Optische mikroskopie mit lichtumwandelbaren optischen etiketten
DE102006030976A1 (de) 2006-07-03 2008-01-17 Behrens, Meinhard, Dr. Verfahren zum qualitativen Nachweis von zugesetzten Eiweiß-Stoffen in Lebensmitteln
EP2677319B1 (de) 2008-07-09 2015-12-30 The Institute for Ethnomedicine Antikörper zum Nachweis von neurotoxischen Aminosäuren, die mit neurologischen Krankheiten assoziiert sind
CN102234240B (zh) * 2011-05-05 2014-04-09 江苏弘和药物研发有限公司 L-bmaa盐酸盐的合成方法
WO2013078395A1 (en) 2011-11-21 2013-05-30 The Institute For Ethnomedicine L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
US8394596B1 (en) 2012-04-13 2013-03-12 Abraxis LLC Antibodies and assays for beta-N-methylamino-L-alanine
ITRM20130253A1 (it) * 2013-04-29 2014-10-30 Canox4Drug S P A Metodo per la determinazione del rame libero
CN103837620A (zh) * 2014-03-21 2014-06-04 上海硕源健标生物医学科技有限公司 一种同时检测人体血浆中多种氨基酸含量的方法
CN106053678A (zh) * 2016-08-16 2016-10-26 汤臣倍健股份有限公司 一种辅助降血糖片深加工产品中4‑羟基异亮氨酸含量的检测方法
CN107157793A (zh) * 2017-07-05 2017-09-15 芜湖凌梦电子商务有限公司 一种营养洗发香波
CN107157790A (zh) * 2017-07-05 2017-09-15 芜湖凌梦电子商务有限公司 营养去屑洗发香波
CN107334651A (zh) * 2017-07-05 2017-11-10 芜湖凌梦电子商务有限公司 一种营养去屑洗发香波
CN109524112A (zh) * 2018-12-26 2019-03-26 杭州电子科技大学 一种基于部分定向相干法的脑功能网络构建方法
CN116593706A (zh) * 2021-07-07 2023-08-15 北京常友生物科技有限公司 以β-甲氨基-L-丙氨酸为靶点在制备检测孤独症试剂盒中的应用
CN118556642A (zh) * 2024-06-05 2024-08-30 北京常友生物科技有限公司 一种利用神经毒素诱导大鼠孤独症模型的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5824554A (en) * 1994-09-09 1998-10-20 Mckay; Florine M. Detection of allergenic substances in food products
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
NZ514414A (en) * 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
CN1341610A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——运动神经障碍相关蛋白62.15和编码这种多肽的多核苷酸
AU2002223317A1 (en) 2000-11-03 2002-05-15 The University Of British Columbia Sterol glucoside toxins
WO2005019830A1 (en) * 2003-08-12 2005-03-03 Institute For Ethnomedicine Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders

Also Published As

Publication number Publication date
HK1090696A1 (en) 2006-12-29
US7901895B2 (en) 2011-03-08
CA2535663A1 (en) 2005-03-03
EP1664793B1 (de) 2007-11-07
EP1860441B1 (de) 2011-08-10
US7256002B2 (en) 2007-08-14
US20050042686A1 (en) 2005-02-24
ATE520033T1 (de) 2011-08-15
CN100595588C (zh) 2010-03-24
US20070292893A1 (en) 2007-12-20
US20140080140A1 (en) 2014-03-20
JP4312203B2 (ja) 2009-08-12
AU2003296424A1 (en) 2005-03-10
US7670783B2 (en) 2010-03-02
DE60317379T2 (de) 2008-09-11
US20110183424A1 (en) 2011-07-28
JP2007521464A (ja) 2007-08-02
US20070254315A1 (en) 2007-11-01
EP1664793B9 (de) 2008-07-16
US8541184B2 (en) 2013-09-24
DK1664793T3 (da) 2008-01-28
CA2535663C (en) 2011-02-08
DE60317379D1 (de) 2007-12-20
EP1860441A2 (de) 2007-11-28
EP1860441A3 (de) 2008-03-05
US10048278B2 (en) 2018-08-14
CN1860369A (zh) 2006-11-08
EP1664793A1 (de) 2006-06-07
WO2005019830A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
DE60317379D1 (de) Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen
DE602004017201D1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
DK1200832T3 (da) Annexiner og autoantistoffer anvendt som markörer for lungecancer og ösofageal cancer
WO2007076129A3 (en) Nanoreporters and methods of manufacturing and use thereof
EP1912674A4 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
WO2006074947A3 (en) METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
ATE432470T1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
WO2009137015A3 (en) Biomarkers of ionizing radiation
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
WO2006107962A8 (en) Methods and products for evaluating an immune response to a therapeutic protein
ATE504001T1 (de) Verfahren zur diagnose oder überwachung eines fehlers im zuckerstoffwechsel
WO2003042659A3 (en) Rapid prion-detection assay
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
ATE462001T1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
FI20031370A0 (fi) Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
EP1545554A4 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
WO2002010456A3 (en) Multiparameter analysis for predictive medicine
DE602004026439D1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
ATE462140T1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1664793

Country of ref document: EP